In this regard, since GSK3β inhibition potentiates the profibrotic phenotype in monocyte-derived macrophage through MAFB, the pharmacological modulation of the GSK3β/MAFB axis appears as a promising strategy for macrophage reprogramming in COVID-19. Here, MAFB is linked to COVID-19.